A Decade of Gabapentinoid Misuse: An Analysis of the European Medicines Agency’s ‘Suspected Adverse Drug Reactions’ Database
Open accessThe DOI matches its Crossref record; 67 of the 68 references it cites were found in a registry or an index.
Abstract
Introduction The gabapentinoids pregabalin and gabapentin are being increasingly prescribed for a range of clinical conditions. Recently, although gabapentinoids at therapeutic dosages may present with low addictive liability levels, cases of misuse and rising numbers of related fatalities have been reported.Objectives The aim of the study was to identify and assess cases of gabapentinoid misuse or dependence as reported to the European Medicines Agency's EudraVigilance database, to identify the magnitude of this problem and the characteristics of these reactions.Methods All spontaneous reports of both gabapentin- (2004-2015) and pregabalin- (2006-2015) related misuse/abuse/dependence were retrieved. A descriptive analysis by source, sex, age, and type of report was performed.Results From the EudraVigilance database 7639 (6.6 % of a total of 115,616) and 4301 (4.8 % of 90,166) adverse drug reaction reports of misuse/abuse/dependence were, respectively, associated with pregabalin and gabapentin, with an overall reporting frequency increasing over time. For both molecules, subjects typically involved were female adults. A total of 27 and 86 fatalities, respectively, associated with pregabalin and gabapentin, and mostly in combination with opioids, were identified. Analysis of proportional reporting ratios for drug abuse/dependence/intentional product misuse values seem to indicate that these adverse drug reactions were more frequently reported for pregabalin (1.25, 1.39, and 1.58, respectively) compared with gabapentin.Conclusions Despite data collection/methodological approach limitations, the present data seem to suggest that gabapentinoid misuse may be a cause for concern, especially in patients with a history of substance misuse. Hence, healthcare professionals should be vigilant when prescribing these molecules.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“All these actions are likely contributing to both its significant psychoactive effects and addictive liability issues (43-44; Table 1).”
From Coming Off Prescribed Psychotropic Medications: Insights from Their Use as Recreational Drugs (2020) · cites this paper as [43]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Comparison of the Pharmacokinetics and Pharmacodynamics of Pregabalin and Gabapentin
Bockbrader, H. N., Wesche, D., Miller, R., Chapel, S., Janiczek, N., & Burger, P. (2010) · Clinical Pharmacokinetics · doi:10.2165/11536200-000000000-00000 · Cited by 690
Pharmaceutical Overdose Deaths, United States, 2010
Jones, C. M., Mack, K. A., & Paulozzi, L. J. (2013) · JAMA · doi:10.1001/jama.2013.272 · Cited by 678
Novel psychoactive substances of interest for psychiatry
Schifano, F., Orsolini, L., Duccio Papanti, G., & Corkery, J. M. (2015) · World Psychiatry · doi:10.1002/wps.20174 · Cited by 321
Self-citationNagakura, Y., Oe, T., Aoki, T., & Matsuoka, N. (2009) · Pain · doi:10.1016/j.pain.2009.05.024 · Cited by 256
Misuse and Abuse of Pregabalin and Gabapentin: Cause for Concern?
Schifano, F. (2014) · CNS Drugs · doi:10.1007/s40263-014-0164-4 · Cited by 250
Self-citationSchifano, F., D’Offizi, S., Piccione, M., Corazza, O., Deluca, P., Davey, Z., Di Melchiorre, G., Di Furia, L., Farré, M., Flesland, L., et al. (2011) · Psychotherapy and Psychosomatics · doi:10.1159/000321079 · Cited by 187
Self-citationSchwan, S., Sundström, A., Stjernberg, E., Hallberg, E., & Hallberg, P. (2010) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-010-0853-y · Cited by 169
Baird, C. R. W., Fox, P., & Colvin, L. A. (2014) · European Addiction Research · doi:10.1159/000355268 · Cited by 146
Pregabalin abuse and dependence in Germany: results from a database query
Gahr, M., Freudenmann, R. W., Hiemke, C., Kölle, M. A., & Schönfeldt‐Lecuona, C. (2013) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-012-1464-6 · Cited by 143
Profiles of pregabalin and gabapentin abuse by postmortem toxicology
Häkkinen, M., Vuori, E., Kalso, E. A., Gergov, M., & Ojanperä, I. A. (2014) · Forensic Science International · doi:10.1016/j.forsciint.2014.04.028 · Cited by 139
Research works printed but not linked: 1
- Sweet AD. Pregabalin abuse and the risks associated for patients with a previous history of substance misuse. J Addict Res Ther. 2013;4:e116.
Cited by
Abuse and Misuse of Pregabalin and Gabapentin
Evoy, K. E., Morrison, M. D., & Saklad, S. R. (2017) · Drugs · doi:10.1007/s40265-017-0700-x · Cited by 410
How addictive are gabapentin and pregabalin? A systematic review
Bonnet, U., & Scherbaum, N. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.08.430 · Cited by 281
“Among them, there were 6 detailed postmortem case reports with gabapentin assumed to be the main cause of death (Moore et al., 2005; Middleton, 2011; Cantrell et al., 2015; Chiappini and Schifano, 2016).”
BackgroundMethodInfluentialTompkins, D. A., Hobelmann, J. G., & Compton, P. (2017) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2016.12.002 · Cited by 249
“There is also increasing evidence that patients may misuse or abuse gabapentin (Chiappini and Schifano, 2016; Smith et al., 2016).”
BackgroundAbuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update
Evoy, K. E., Sadrameli, S., Contreras, J., Covvey, J. R., Peckham, A. M., & Morrison, M. D. (2021) · Drugs · doi:10.1007/s40265-020-01432-7 · Cited by 240
Trial of pregabalin for acute and chronic sciatica
Mathieson, S., Maher, C. G., McLachlan, A. J., Latimer, J., Koes, B. W., Hancock, M. J., Harris, I., Day, R. O., Billot, L., Pik, J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614292 · Cited by 219
Metadata
- Authors
- Chiappini, S., & Schifano, F.
- Affiliations
- Università Cattolica del Sacro Cuore (IT)
- University of Hertfordshire (GB)
- Corresponding author
- Chiappini, Stefania
- Venue
- CNS Drugs
- Published
- 2016-06-16
- Volume
- 30
- Issue
- 7
- Pages
- 647-654
- ISSN
- 1172-7047 (ISSN-L)
- 1179-1934
- OpenAlex
- W2424370328
- Cited by
- 189
- References
- 68
- Citations by year
- 2026: 8 · 2025: 18 · 2024: 15 · 2023: 19 · 2022: 18 · 2021: 30 · 2020: 20 · 2019: 19 · 2018: 18 · 2017: 22 · 2016: 2
- FWCI
- 20.16
- Type
- journal article
- Language
- en
- Open access
- green
- uhra.herts.ac.uk
- Locations
- CNS Drugs (publishedVersion)
- PubMed (publishedVersion)
- University of Hertfordshire Research Archive (University of Hertfordshire) (acceptedVersion)
- University of Hertfordshire Research Archive (University of Hertfordshire) (submittedVersion)
- Funders
- European Commission (Drug Prevention and Information Programme 2014-16, contract no. JUST/2013/DPIP/AG/4823, EU-MADNESS project)
- Directorate-General for Justice (JUST/2013/ISEC/DRUGS/AG/6429) Project EPS/NP)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- gabapentinoids, gabapentin, pregabalin, drug abuse, substance dependence, adverse drug reactions, EudraVigilance, drug-related deaths, opioid combination, proportional reporting ratio
- MeSH terms
- Pregabalin, Gabapentin, Adult, Amines, Analgesics, Opioid, Cyclohexanecarboxylic Acids, Female, gamma-Aminobutyric Acid, Humans, Male, Middle Aged, Databases, Factual, Behavior, Addictive, Substance-Related Disorders, Prescription Drug Misuse
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Decade of Gabapentinoid Misuse: An Analysis of the European Medicines Agency’s ‘Suspected Adverse Drug Reactions’ Database. https://app.cochat.ai/papers/10.1007/s40263-016-0359-y
- The paper
- Chiappini, S., & Schifano, F. (2016). A Decade of Gabapentinoid Misuse: An Analysis of the European Medicines Agency’s ‘Suspected Adverse Drug Reactions’ Database. CNS Drugs. https://doi.org/10.1007/s40263-016-0359-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.